Breast Cancer Clinical Trial

A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast Cancer

Summary

This is a multicenter, open label, Phase 1b study in patients with mBC. This study will have a dose escalation to identify the maximum tolerated dose (MTD) of the combination of gedatolisib plus palbociclib/fulvestrant and gedatolisib plus palbociclib/letrozole and expansion to estimate the objective response rate (OR) of the combination of gedatolisib plus palbociclib/letrozole or palbociclib/fulvestrant.

View Full Description

Full Description

This is a multicenter, open label, continuous Phase 1b study in patients with MBC. This study will have a dose escalation and expansion. The dose escalation will identify the maximum tolerated dose (MTD) of the combination of gedatolisib plus palbociclib/fulvestrant and gedatolisib plus palbociclib/letrozole. The expansion will estimate the objective response rate (OR) of the combination of gedatolisib plus palbociclib/letrozole and the combination of gedatolisib plus palbociclib/fulvestrant.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Women 18 years of age or older, who are either: Postmenopausal or Pre/perimenopausal women with medically-induced menopause by treatment with agents to induce chemical menopause.
Histologically or cytologically proven diagnosis of breast cancer with evidence of metastasis.
Documentation of estrogen receptor positive ((ER+), human epidermal growth factor receptor 2 (HER2 negative (HER2-)) tumor.

Dose Escalation Portion: Patients must satisfy one of the following criteria:

Letrozole combination cohort (L): metastatic breast cancer (MBC) with progression who are candidates for a letrozole-containing regimen, with palbociclib.
Fulvestrant combination cohort (F): MBC with progression who are candidates for a fulvestrant containing regimen, with palbociclib.

Dose Expansion Portion: Patients must satisfy one of the following criteria:

Arm A: MBC with progression and no prior endocrine based systemic therapy in the metastatic setting;
Arm B: MBC with progression during or following one prior endocrine based systemic therapy in the metastatic setting, with no prior therapy with any cyclin-dependent kinase (CDK) inhibitor;
Arm C/Arm D: MBC with progression during or following one or two prior endocrine based systemic therapies in the metastatic setting, and following prior therapy with a CDK inhibitor.
Measurable disease as defined by Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1.
Bone only patients during dose escalation portion.
Availability of archival tumor biopsy sample or willing to provide fresh biopsy if not available.
Eastern Cooperative Oncology Group [ECOG] performance must be 0 or 1.
Adequate bone marrow, renal and liver function.

Exclusion Criteria:

Prior treatment with a mechanistic target of rapamycin (mTOR) inhibitor or phosphoinositide 3-kinase (PI3K) inhibitor.
More than 1 line of prior chemotherapy in the treatment of metastatic or locally advanced/recurrent disease.
Bone only patients during expansion/efficacy portion.
Patients with advanced/metastatic disease who have symptomatic visceral spread, and who have life threatening complications needing immediate therapy, such as massive uncontrolled effusions [pleural, pericardial, peritoneal], pulmonary lymphangitis, and over 50% liver replacement with tumor.
Known active uncontrolled or symptomatic Central Nervous System (CNS) metastases.
Active bacterial, fungal or viral infection.
Uncontrolled or significant cardiovascular disease.
Radiation therapy within 4 weeks of investigational product.
Cytotoxic chemotherapy within 4 weeks of investigational product (6 weeks for mitomycin C or nitrosoureas) if immediate prior regimen was administered on an every 3 4 week schedule or 2 weeks of investigational product if immediate prior regimen consisted of weekly therapy.
Any other anti cancer agents (eg, hormonal, biological, investigational) within 5 times the half life prior to investigational product.
Impairment of gastro intestinal (GI) function or GI disease.
Pregnant female patients; breastfeeding female patients; and female patients of childbearing potential who are unwilling or unable to use 2 highly effective methods of contraception as outlined in this protocol for the duration of the study and for 90 days.

Study is for people with:

Breast Cancer

Phase:

Phase 1

Estimated Enrollment:

141

Study ID:

NCT02684032

Recruitment Status:

Completed

Sponsor:

Celcuity, Inc.

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 26 Locations for this study

See Locations Near You

University of Alabama at Birmingham
Birmingham Alabama, 35233, United States
University of Alabama at Birmingham
Birmingham Alabama, 35249, United States
Compassionate Care Research Group Inc. at Compassionate Cancer Care Medical Group, Inc.
Corona California, 92879, United States
Compassionate Care Research Group Inc. at Compassionate Cancer Care Medical Group, Inc.
Fountain Valley California, 92708, United States
Keck Hospital of USC - Norris Healthcare Center (HC3)
Los Angeles California, 90033, United States
Keck Hospital of USC
Los Angeles California, 90033, United States
LAC+USC Medical Center
Los Angeles California, 90033, United States
USC/Norris Comprehensive Cancer Center / Investigational Drug Services
Los Angeles California, 90033, United States
USC/Norris Comprehensive Cancer Center
Los Angeles California, 90033, United States
Compassionate Care Research Group Inc. at Compassionate Cancer Care Medical Group, Inc.
Riverside California, 92501, United States
UCSF - Helen Diller Family Comprehensive Cancer Center
San Francisco California, 94115, United States
UCSF - Helen Diller Family Comprehensive Cancer Center
San Francisco California, 94158, United States
University of Colorado Hospital - Anschutz Inpatient Pavilion (AiP)
Aurora Colorado, 80045, United States
University of Colorado Hospital - Anschutz Outpatient Pavilion (AOP)
Aurora Colorado, 80045, United States
University of Colorado Hospital - Clinical Trials Office (CTO)
Aurora Colorado, 80045, United States
University of Colorado Hospital- Anschutz Cancer Pavilion (ACP)
Aurora Colorado, 80045, United States
Moffitt Cancer Center Richard M Schulze Family Foundation Outpatient Center at McKinley Campus
Tampa Florida, 33612, United States
Moffitt Cancer Center
Tampa Florida, 33612, United States
Emory University Hospital Midtown
Atlanta Georgia, 30308, United States
Emory University Hospital
Atlanta Georgia, 30322, United States
The Emory Clinic
Atlanta Georgia, 30322, United States
Winship Cancer Institute
Atlanta Georgia, 30322, United States
Massachusetts General Hospital
Boston Massachusetts, 02114, United States
University of Michigan
Ann Arbor Michigan, 48109, United States
Karmanos Cancer Institute
Detroit Michigan, 48201, United States
Karmanos Cancer Institute
Farmington Hills Michigan, 48334, United States
UNC Cancer Hospital Infusion Pharmacy
Chapel Hill North Carolina, 27514, United States
UNC Hospitals, The University of North Carolina at Chapel Hill
Chapel Hill North Carolina, 27514, United States
Ohio State University Comprehensive Cancer Center
Columbus Ohio, 43210, United States
The Ohio State University Wexner Medical Center James Cancer Hospital
Columbus Ohio, 43210, United States
Stefanie Spielman Comprehensive Breast Cancer
Columbus Ohio, 43212, United States
Thomas Jefferson University - Clinical and Regulatory
Philadelphia Pennsylvania, 19107, United States
Thomas Jefferson University
Philadelphia Pennsylvania, 19107, United States
Vanderbilt Breast Center at One Hundred Oaks
Nashville Tennessee, 37204, United States
Henry-Joyce Cancer Clinic
Nashville Tennessee, 37232, United States
The University of Texas MD Anderson Cancer Center
Houston Texas, 77030, United States
U.T. MD Anderson Cancer Center
Houston Texas, 77030, United States
Virginia Cancer Specialists, PC
Fairfax Virginia, 22031, United States
Seattle Cancer Care Alliance (SCCA) Investigational Drug Services
Seattle Washington, 98109, United States
Seattle Cancer Care Alliance
Seattle Washington, 98109, United States
University of Washington Medical Center
Seattle Washington, 98195, United States

How clear is this clinincal trial information?

Study is for people with:

Breast Cancer

Phase:

Phase 1

Estimated Enrollment:

141

Study ID:

NCT02684032

Recruitment Status:

Completed

Sponsor:


Celcuity, Inc.

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider